Literature DB >> 19965573

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.

Philip J Barter1, Gunnar Brandrup-Wognsen, Mike K Palmer, Stephen J Nicholls.   

Abstract

The relationship between statin-induced increases in HDL cholesterol (HDL-C) concentration and statin-induced decreases in LDL cholesterol (LDL-C) is unknown. The effects of different statins on HDL-C levels, relationships between changes in HDL-C and changes in LDL-C, and predictors of statin-induced increases in HDL-C have been investigated in an individual patient meta-analysis of 32,258 dyslipidemic patients included in 37 randomized studies using rosuvastatin, atorvastatin, and simvastatin. The HDL-C raising ability of rosuvastatin, and simvastatin was comparable, with both being superior to atorvastatin. Increases in HDL-C were positively related to statin dose with rosuvastatin and simvastatin but inversely related to dose with atorvastatin. There was no apparent relationship between reduction in LDL-C and increase in HDL-C, whether analyzed overall for all statins (correlation coefficient = 0.005) or for each statin individually. Percentage increase in apolipoprotein A-I was virtually identical to that of HDL-C at all doses of the three statins. Baseline concentrations of HDL-C and triglyceride (TG) and presence of diabetes were strong, independent predictors of statin-induced elevations of HDL-C. Statins vary in their HDL-C raising ability. The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965573      PMCID: PMC3035518          DOI: 10.1194/jlr.P002816

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  36 in total

Review 1.  Coronary atherosclerosis can regress with very intensive statin therapy.

Authors:  Ilke Sipahi; Stephen J Nicholls; E Murat Tuzcu; Steven E Nissen
Journal:  Cleve Clin J Med       Date:  2006-10       Impact factor: 2.321

2.  The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase.

Authors:  Andrea Kassai; László Illyés; Hossein Z Mirdamadi; Ildiko Seres; Tímea Kalmár; Mária Audikovszky; György Paragh
Journal:  Clin Biochem       Date:  2006-06-09       Impact factor: 3.281

3.  Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.

Authors:  Bela F Asztalos; Florence Le Maulf; Gerald E Dallal; Evan Stein; Peter H Jones; Katalin V Horvath; Fergus McTaggart; Ernst J Schaefer
Journal:  Am J Cardiol       Date:  2007-01-04       Impact factor: 2.778

Review 4.  Comparison of statins in hypertriglyceridemia.

Authors:  E A Stein; M Lane; P Laskarzewski
Journal:  Am J Cardiol       Date:  1998-02-26       Impact factor: 2.778

5.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

6.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

Authors:  Stephen J Nicholls; E Murat Tuzcu; Ilke Sipahi; Adam W Grasso; Paul Schoenhagen; Tingfei Hu; Kathy Wolski; Tim Crowe; Milind Y Desai; Stanley L Hazen; Samir R Kapadia; Steven E Nissen
Journal:  JAMA       Date:  2007-02-07       Impact factor: 56.272

7.  Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.

Authors:  Ole Faergeman; Laurie Hill; Eberhard Windler; Olov Wiklund; Roland Asmar; Emma Duffield; Froukje Sosef
Journal:  Cardiology       Date:  2008-04-23       Impact factor: 1.869

8.  Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status.

Authors:  Norimasa Tamehiro; Yukari Shigemoto-Mogami; Tomoshi Kakeya; Kei-Ichiro Okuhira; Kazuhiro Suzuki; Ryuichiro Sato; Taku Nagao; Tomoko Nishimaki-Mogami
Journal:  J Biol Chem       Date:  2007-05-27       Impact factor: 5.157

Review 9.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

Review 10.  Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

Authors:  Fergus McTaggart; Peter Jones
Journal:  Cardiovasc Drugs Ther       Date:  2008-06-14       Impact factor: 3.727

View more
  62 in total

Review 1.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.

Authors:  Keith K Lau; Daniel J Tancredi; Richard V Perez; Lavjay Butani
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

3.  Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.

Authors:  Audrey Y Chu; Franco Giulianini; Bryan J Barratt; Bo Ding; Fredrik Nyberg; Samia Mora; Paul M Ridker; Daniel I Chasman
Journal:  Circ Cardiovasc Genet       Date:  2015-08-13

Review 4.  Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance.

Authors:  Arshag D Mooradian; Michael J Haas
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

5.  Leptin and cardiovascular health in high body mass index.

Authors:  Chee H Liew; Wee H Sim; Ernest Z Low; Bernard C M Chan
Journal:  Ir J Med Sci       Date:  2020-07-02       Impact factor: 1.568

Review 6.  Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.

Authors:  Hisato Takagi; Masao Niwa; Yusuke Mizuno; Hirotaka Yamamoto; Shin-nosuke Goto; Takuya Umemoto
Journal:  Heart Vessels       Date:  2013-05-05       Impact factor: 2.037

Review 7.  The effects of statin medications on aerobic exercise capacity and training adaptations.

Authors:  Zsolt Murlasits; Zsolt Radák
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

Review 8.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

9.  Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.

Authors:  Alexina Orsoni; Patrice Thérond; Ricardo Tan; Philippe Giral; Paul Robillard; Anatol Kontush; Peter J Meikle; M John Chapman
Journal:  J Lipid Res       Date:  2016-08-31       Impact factor: 5.922

10.  Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression.

Authors:  Mingming Gao; Dong Zhao; Sarah Schouteden; Mary G Sorci-Thomas; Paul P Van Veldhoven; Kristel Eggermont; George Liu; Catherine M Verfaillie; Yingmei Feng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-26       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.